Form Number: CMS–10891 (OMB control number: 0938–TBD); *Frequency:* Occasionally; *Affected Public:* State, Local and Tribal Governments and Individuals or households; *Number of Respondents:* 3,460,750; *Total Annual Responses:* 3,460,750; *Total Annual Hours:* 5,517,157. (For policy questions regarding this collection contact: Melissa Heitt at 410–786–2484.)

William N. Parham, III

Director, Division of Information Collections and Regulatory Impacts, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. 2024–27871 Filed 11–26–24; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–3471–N]

Medicare Program; Public Meeting for Air Ambulance Quality & Patient Safety Advisory Committee—December 12, 2024, February 18, 2025, and May 8, 2025

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice of meeting.

SUMMARY: This notice announces virtual public meetings of the Air Ambulance Quality and Patient Safety (AAQPS) Advisory Committee. The AAQPS Advisory Committee will review options to establish quality, patient safety, and clinical capability standards for each clinical capability level of air ambulances.

DATES: *Virtual Meeting Dates:* The AAQPS Advisory Committee will hold virtual meetings on December 12, 2024, February 18, 2025, and May 8, 2025, from 10:00 a.m. to 5:00 p.m., Eastern Time (E.T.).

Deadline for Submitting Requests for Special Accommodations: Requests for special accommodations must be received at least 2 weeks before each meeting.

Registration Link: The virtual meetings will be open to the public and held via the Zoom webinar platform. Virtual attendance information will be provided upon registration. To register for the virtual meeting, please visit: *https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety.* Attendance is open to the public subject to any technical or capacity limitations.

Deadline for Registration: All individuals who plan to attend the virtual public meeting must register to attend. Request to provide oral comments are due at least fourteen (14) calendar days prior to the meeting date. Interested parties are encouraged to register as far in advance of the meeting as possible.

A detailed agenda and materials will be available prior to the meeting on the AAQPS Advisory Committee website at: *https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety.*

A recording and a summary of the meeting will be made available on the AAQPS Advisory Committee website approximately 45 calendar days after the meeting.

ADDRESSES: *Virtual Meeting Location:* All meetings are open to the public and instructions to view will be posted on the AAQPS Advisory Committee website, and upon registration. If you wish to provide oral comments during the meetings you must complete a registration form on the AAQPS Advisory Committee website at: *https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety,* and submit a written copy of your remarks to *AAQPS@cms.hhs.gov.*

FOR FURTHER INFORMATION CONTACT: Ashley Spence, CMS, at (410) 786–2000 or via email at *AAQPS@cms.hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Background

The Secretary of the Department of Health and Human Services (HHS) and the Secretary of Transportation established the Air Ambulance Quality and Patient Safety (AAQPS) Advisory Committee on August 22, 2023, in response to section 106 of the No Surprises Act, enacted as part of the Consolidated Appropriations Act, 2021, div. BB, tit. I, Public Law 116–260 (December 27, 2020). The AAQPS Advisory Committee will be tasked with reviewing options to establish quality, patient safety, and clinical capability standards for each clinical capability level of air ambulances.

The AAQPS Advisory Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463 (Oct. 6, 1972), as amended by 5 U.S.C. app. 2.

II. Advisory Committee Membership Roster

On June 2, 2023, HHS published an Invitation for Member Nominations in the **Federal Register** for the AAQPS Advisory Committee (88 FR 37253). This notice also announces the members of the AAQPS Advisory Committee.

- Jeff Richey—HHS Secretary's Designee/Representative.
- Robert Reckert—DoT Secretary's Designee/Representative.
- Ben Clayton—DoT Representative.
- Colonel Steven L. Coffee—Patient Advocate.
- Dr. Jordan Pritzker—Group Health Plans and Health Insurance Issuers.
- Dr. Mark Gamber—HHS Representative.
- Dr. William Hinckley—Healthcare Provider.
- Eileen Frazer—Accrediting bodies.
- Grace Arnold—State Insurance Regulator.
- Jason Clark—HHS Representative.
- Jason Quisling—DoT Representative.
- Jeff Houser—DoT Representative.
- Paul Julander—DoT Representative.
- Thomas Judge—DoT Representative.

III. Summary of the Agenda

During the December 12, 2024, February 18, 2025, and May 8, 2025 meetings, the AAQPS Advisory Committee will review options to establish quality, patient safety, and clinical capability standards for each clinical capability level of air ambulances. A more detailed agenda and meeting materials will be made available 3 days before the meetings on the AAQPS Advisory Committee website at *https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety.*

IV. Public Participation

The meetings will be open to the public for virtual attendance on a first-come, first-served basis, as there may be capacity or technical limitations. Please see the **ADDRESSES** section to view the meeting link.

The Department is committed to providing equal access to this meeting for all participants. If you need alternative formats or services because of a disability, such as sign language interpreter, please contact the person listed in the **FOR FURTHER INFORMATION CONTACT** section no later than 2 weeks before each meeting.

The Department will accept oral comments, which must be limited to the objectives of the committee and limited to three (3) minutes per person. Individual members of the public who wish to present oral comments must register and provide a written copy of prepared remarks for inclusion in the meeting records and for circulation to

AAQPS Advisory Committee members. All prepared remarks submitted on time will be considered as part of the meeting's record.

V. Submitting Written Comments

Members of the public may submit written comments for consideration by the Committee at any time via email to *AAQPS@cms.hhs.gov.* Additionally, members of the public will have the opportunity to submit comments during the December 12, 2024, February 18, 2025, and May 8, 2025, virtual meetings through the chat feature of the Zoom webinar platform. Members of the public are encouraged to submit lengthy written comments (more than three sentences) to the email address above. Advance submissions that become part of the committee deliberations will become part of the official record of the meeting.

The Administrator of CMS, Chiquita Brooks-LaSure, having reviewed and approved this document, authorizes Vanessa Garcia, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the **Federal Register**.

Vanessa Garcia,

Federal Register Liaison, Centers for Medicare & Medicaid Services.

[FR Doc. 2024–27740 Filed 11–26–24; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2018–N–3236]

Advisory Committee; Oncologic Drugs Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of Federal advisory committee.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2026, expiration date.

DATES: Authority for the Oncologic Drugs Advisory Committee will expire on September 1, 2026, unless the Commissioner formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Yvette Waples, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301–796–9001, *ODAC@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102–3.65 and approval by the Department of Health and Human Services and by the General Services Administration, FDA is announcing the renewal of the Oncologic Drugs Advisory Committee (the Committee). The Committee is a discretionary Federal advisory committee established to provide advice to the Commissioner. The Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which FDA has regulatory responsibility.

The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate recommendations to the Commissioner.

Pursuant to its charter, the Committee shall consist of a core of 13 voting members, including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of general oncology, pediatric oncology, hematologic oncology, immunology oncology, biostatistics, and other related professions. Members will be invited to serve for overlapping terms of up to 4 years. Non-Federal members of this committee will serve as Special Government Employees or representatives. Federal members will serve as Regular Government Employees or Ex-Officios. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting representative member who is identified with industry interests. There may also be an alternate industry representative.

The Commissioner or designee shall have the authority to select members of other scientific and technical FDA advisory committees (normally not to exceed 10 members) to serve temporarily as voting members and to designate consultants to serve temporarily as voting members when: (1) expertise is required that is not available among current voting standing members of the Committee (when additional voting members are added to the Committee to provide needed expertise, a quorum will be based on the combined total of regular and added members) or (2) to comprise a quorum when, because of unforeseen circumstances, a quorum is or will be lacking. Because of the size of the Committee and the variety in the types of issues that it will consider, FDA may, in connection with a particular committee meeting, specify a quorum that is less than a majority of the current voting members. The Agency's regulations (21 CFR 14.22(d)) authorize a committee charter to specify quorum requirements.

If functioning as a medical device panel, an additional non-voting representative member of consumer interests and an additional non-voting representative member of industry interests will be included in addition to the voting members.

Further information regarding the most recent charter and other information can be found at *https://www.fda.gov/advisory-committees/oncologic-drugs-advisory-committee/oncologic-drugs-advisory-committee-roster* or by contacting the Designated Federal Officer (see **FOR FURTHER INFORMATION CONTACT**). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.

This notice is issued under the Federal Advisory Committee Act as amended (5 U.S.C. 1001 *et seq.*). For general information related to FDA advisory committees, please visit us at *http://www.fda.gov/AdvisoryCommittees/default.htm.*

Dated: November 19, 2024.

P. Ritu Nalubola,

Associate Commissioner for Policy.

[FR Doc. 2024–27797 Filed 11–26–24; 8:45 am]

BILLING CODE 4164–01–P